The prevalence and burden of bipolar disorder: findings from the Global Burden of Disease Study 2013

Ferrari, Alize J.; Stockings, Emily; Khoo, Jon Paul; Erskine, Holly E.; Degenhardt, Louisa; Vos, Theo; Whiteford, Harvey

doi:10.1111/bdi.12423

Cited by 467 publications

(301 citation statements)

References 44 publications

Supporting

Mentioning

270

Contrasting

Unclassified

Order By: Relevance

“…This result agrees with a recent epidemiological study 24 and is likely due to a strong link between the female reproductive hormonal axis and regulatory mechanisms of sunlight sensitivity. 17 Second, a difference in mean age was found.…”

Section: Discussionsupporting

confidence: 93%

Bipolar disorders: is there an influence of seasonality or photoperiod?

Aguglia

Borsotti

Maina

2017

Rev. Bras. Psiquiatr.

View full text Add to dashboard Cite

Objective: To increase understanding of the influence of photoperiod variation in patients with bipolar disorders. Methods: We followed a sample of Italian bipolar patients over a period of 24 months, focusing on inpatients. All patients admitted to the Psychiatric Inpatient Unit of San Luigi Gonzaga Hospital in Orbassano (Turin, Italy) between September 1, 2013 and August 31, 2015 were recruited. Sociodemographic and clinical data were collected. Results: Seven hundred and thirty patients were included. The admission rate for bipolar patients was significantly higher during May, June and July, when there was maximum sunlight exposure, although no seasonal pattern was found. Patients with (hypo)manic episodes were admitted more frequently during the spring and during longer photoperiods than those with major depressive episodes. Conclusions: Photoperiod is a key element in bipolar disorder, not only as an environmental factor but also as an important clinical parameter that should be considered during treatment.

show abstract

Section: Discussionsupporting

confidence: 93%

Bipolar disorders: is there an influence of seasonality or photoperiod?

Aguglia

Borsotti

Maina

2017

Rev. Bras. Psiquiatr.

View full text Add to dashboard Cite

show abstract

“…Consistent with these observations, the Global Burden of Disease Study attributed 9.9 million years lost to disability (YLD) to BD, making it the 16 th leading cause of YLD worldwide 24. The impact that BD has on young people is even greater, with being the sixth leading cause of disability‐adjusted life years among people aged 10‐24 years worldwide 25.…”

Section: Foundations Of Managementmentioning

confidence: 90%

Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder

et al. 2018

View full text Add to dashboard Cite

The Canadian Network for Mood and Anxiety Treatments (CANMAT) previously published treatment guidelines for bipolar disorder in 2005, along with international commentaries and subsequent updates in 2007, 2009, and 2013. The last two updates were published in collaboration with the International Society for Bipolar Disorders (ISBD). These 2018 CANMAT and ISBD Bipolar Treatment Guidelines represent the significant advances in the field since the last full edition was published in 2005, including updates to diagnosis and management as well as new research into pharmacological and psychological treatments. These advances have been translated into clear and easy to use recommendations for first, second, and third‐ line treatments, with consideration given to levels of evidence for efficacy, clinical support based on experience, and consensus ratings of safety, tolerability, and treatment‐emergent switch risk. New to these guidelines, hierarchical rankings were created for first and second‐ line treatments recommended for acute mania, acute depression, and maintenance treatment in bipolar I disorder. Created by considering the impact of each treatment across all phases of illness, this hierarchy will further assist clinicians in making evidence‐based treatment decisions. Lithium, quetiapine, divalproex, asenapine, aripiprazole, paliperidone, risperidone, and cariprazine alone or in combination are recommended as first‐line treatments for acute mania. First‐line options for bipolar I depression include quetiapine, lurasidone plus lithium or divalproex, lithium, lamotrigine, lurasidone, or adjunctive lamotrigine. While medications that have been shown to be effective for the acute phase should generally be continued for the maintenance phase in bipolar I disorder, there are some exceptions (such as with antidepressants); and available data suggest that lithium, quetiapine, divalproex, lamotrigine, asenapine, and aripiprazole monotherapy or combination treatments should be considered first‐line for those initiating or switching treatment during the maintenance phase. In addition to addressing issues in bipolar I disorder, these guidelines also provide an overview of, and recommendations for, clinical management of bipolar II disorder, as well as advice on specific populations, such as women at various stages of the reproductive cycle, children and adolescents, and older adults. There are also discussions on the impact of specific psychiatric and medical comorbidities such as substance use, anxiety, and metabolic disorders. Finally, an overview of issues related to safety and monitoring is provided. The CANMAT and ISBD groups hope that these guidelines become a valuable tool for practitioners across the globe.

show abstract

“…The clinical diagnosis of MDD is based on the presence of either depressed mood or loss of interest and pleasure (anhedonia) for at least 2 weeks, and requires additional symptoms such as weight loss, changes in appetite, insomnia or hypersomnia, psychomotor agitation or retardation, loss of energy or fatigue, feelings of worthlessness, poor concentration, and suicidal thoughts [5]. Both MDD and BPD are among the most disabling mental health disorders worldwide [34,41,85,120] with a lifetime prevalence of~12 [4] and 1% [80], respectively. Based on the 2013 global burden of diseases study by the Institute for Health Metrics and Evaluation at the University of Washington, MDD alone caused an estimated 61.6 million years of life lived with disability worldwide, accounting for 8.1% of the total years lived with disability (YLDs) and for 2.5% of the total disability-adjusted life years [33,41,85].…”

Section: Introductionmentioning

confidence: 99%

“…Based on the 2013 global burden of diseases study by the Institute for Health Metrics and Evaluation at the University of Washington, MDD alone caused an estimated 61.6 million years of life lived with disability worldwide, accounting for 8.1% of the total years lived with disability (YLDs) and for 2.5% of the total disability-adjusted life years [33,41,85]. BPD contributed an additional 9.9 million years of life lived with disability [34].…”

Section: Introductionmentioning

confidence: 99%

Pharmacogenomics in the treatment of mood disorders: Strategies and Opportunities for personalized psychiatry

2017

View full text Add to dashboard Cite

Personalized medicine (personalized psychiatry in a specific setting) is a new model towards individualized care, in which knowledge from genomics and other omic pillars (microbiome, epigenomes, proteome, and metabolome) will be combined with clinical data to guide efforts to new drug development and targeted prescription of the existing treatment options. In this review, we summarize pharmacogenomic studies in mood disorders that may lay the foundation towards personalized psychiatry. In addition, we have discussed the possible strategies to integrate data from omic pillars as a future path to personalized psychiatry. So far, the progress of uncovering single nucleotide polymorphisms (SNPs) underpinning treatment efficacy in mood disorders (e.g., SNPs associated with selective serotonin re-uptake inhibitors or lithium treatment response in patients with bipolar disorder and major depressive disorder) are encouraging, but not adequate. Genetic studies have pointed to a number of SNPs located at candidate genes that possibly influence response to; (a) antidepressants COMT, HTR2A, HTR1A, CNR1, SLC6A4, NPY, MAOA, IL1B, GRIK4, BDNF, GNB3, FKBP5, CYP2D6, CYP2C19, and ABCB1 and (b) mood stabilizers (lithium) 5-HTT, TPH, DRD1, FYN, INPP1, CREB1, BDNF, GSK3β, ARNTL, TIM, DPB, NR3C1, BCR, XBP1, and CACNG2. We suggest three alternative and complementary strategies to implement knowledge gained from pharmacogenomic studies. The first strategy can be to implement diagnostic, therapeutic, or prognostic genetic testing based on candidate genes or gene products. The second alternative is an integrative analysis (systems genomics approach) to combine omics data obtained from the different pillars of omics investigation, including genomics, epigenomes, proteomics, metabolomics and microbiomes. The main goal of system genomics is an identification and understanding of biological pathways, networks, and modules underlying drug-response. The third strategy aims to the development of multivariable diagnostic or prognostic algorithms (tools) combining individual's genomic information (polygenic score) with other predictors (e.g., omics pillars, neuroimaging, and clinical characteristics) to finally predict therapeutic outcomes. An integration of molecular science with that of traditional clinical practice is the way forward to drug discoveries and novel therapeutic approaches and to characterize psychiatric disorders leading to a better predictive, preventive, and personalized medicine (PPPM) in psychiatry. With future advances in the omics technology and methodological developments for data integration, the goal of PPPM in psychiatry is promising.

show abstract

The prevalence and burden of bipolar disorder: findings from the Global Burden of Disease Study 2013

Cited by 467 publications

References 44 publications

Bipolar disorders: is there an influence of seasonality or photoperiod?

Bipolar disorders: is there an influence of seasonality or photoperiod?

Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder

Pharmacogenomics in the treatment of mood disorders: Strategies and Opportunities for personalized psychiatry

Contact Info

Product

Resources

About